ClinicalTrials.gg
CompletedNCT00974311AFFIRMUpdated Dec 11, 2018Results posted

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

A Phase 3 interventional study of Enzalutamide and Placebo in Castration-Resistant Prostate Cancer, sponsored by Pfizer. Completed at 249 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,199
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
6th of 125
1,199 · median 52
Started
2009
the only one that year
Phase 3
16 of 125
1 open now
Registered
3rd of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 16 in phase 3, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

03

Conditions studied

  • Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Castration-resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Progressive prostate cancer
  • Medical or surgical castration with testosterone less than 50 ng/dl
  • One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel
  • (ECOG) performance status 0-2
  • Adequate bone marrow, hepatic, and renal function
  • Able to swallow the study drug and comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • in the brain or active epidural disease
  • Another within the previous 5 years
  • cardiovascular disease
  • Gastrointestinal disorder affecting absorption
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,199 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Formerly MDV3100

    Drug: Enzalutamide

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • MDV3100, 160 mg orally per day

    Also known as: MDV3100, Xtandi

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Survival was defined as time from randomization to death due to any cause. The duration of overall survival was right-censored for participants who were lost to follow-up since randomization or not known to have died at the data analysis cut-off date (this included participants who were known to have died after the data analysis cut-off date).

    Time frame: During study period (up to 101 months)

Secondary outcomes

  1. Radiographic Progression-free Survival

    Radiographic progression-free survival was defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Participants were assessed for objective disease progression at regularly scheduled visits. The consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 were taken into consideration for the determination of disease progression. Radiographic disease progression was defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue disease, or the appearance of two or more new bone lesions on bone scan. Progression at the first scheduled reassessment at Week 13 required a confirmatory scan 6 or more weeks later. Participants who did not reach the endpoint were right censored at their last assessment.

    Time frame: During DB phase (up to 24 months)

  2. Time to First Skeletal-related Event

    The time to first skeletal-related event was defined as time from randomization to the occurrence of the first skeletal-related event. Participants were assessed for skeletal-related events at regularly scheduled visits. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. Participants who did not reach the endpoint were right censored at their last assessment.

    Time frame: During DB Phase (up to 24 months)

  3. Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)

    The FACT-P was a 39-item participant questionnaire which assessed physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The sum of scores on all 5 domains constitutes the global FACT-P. The global/total FACT-P score ranged from 0 (worst) to 156 (best), higher scores indicate better health status. Responders were those participants who had a 10-point improvement in their total FACT-P score, as compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.

    Time frame: Baseline up to 24 months

  4. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was defined as time from randomization to PSA progression. Participants who did not reach the endpoint were right censored at their last assessment or for participants with no post-baseline PSA assessment, date of randomization. For participants with PSA declines at Week 13, the PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 nanogram per milliliter (ng/mL) above the nadir was documented, which was confirmed by a second consecutive value obtained 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment). For participants with no PSA declines at Week 13, PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment).

    Time frame: Baseline and at every study visit from Week 13 while on study drug (up to 24 months)

  5. Percentage of Participants With Pain Palliation

    The proportion of participants with pain palliation was assessed for participants with a stable and sufficient pain burden at study entry. Pain burden was measured by question #3 of the Brief Pain Inventory (Short Form). This scale measures pain on a 0 to 10 scale with 0 indicating no pain and 10 indicating pain as bad as you can imagine. Pain palliation at Week 13 was determined for the proportion of men with baseline bone metastasis(es) who had baseline pain attributable to the metastasis(es). Palliation was defined as \>=30% reduction in average pain score at Week 13 compared to baseline without a \>=30% increase in analgesic use.

    Time frame: Baseline up to 24 months

  6. Percentage of Participants With Prostate Specific Antigen (PSA) Response

    Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \> 50% and \> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.

    Time frame: During DB phase (up to 24 months)

  7. Percentage of Participants With Soft-tissue Objective Response

    The best overall soft tissue response as assessed using RECIST v1.1 during the study was summarized using the investigators' response assessments and also the derived response assessments by treatment group. Only participants with measurable soft tissue disease at screening were included in this analysis. Participants with measurable disease at screening are participants who had at least 1 target lesion identified per RECIST v1.1 at screening. Percentage of participants summarizes the number of participants with complete or partial objective response (%). Soft Tissue assessment based on Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.

    Time frame: During DB phase (up to 24 months)

  8. European Quality of Life Five-Domain (EQ-5D) Scale

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Five parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were assessed on 3-point categorical scale (1= no problems, 2= some/moderate problems and 3= severe problem). Score were transformed and resulted in a total EQ-5D score range of 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health and quality of life.

    Time frame: Week 13

  9. Percentage of Participants With Circulating Tumor Cell (CTC) Conversion

    CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.

    Time frame: Baseline up to 24 months

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes or deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events which occurred between first dose of study drug and up to the safety follow-up visit or the initiation of another anti-neoplastic therapy, whichever occurred first (up to 101 months). AEs included both serious and non-serious AEs. Clinically significant physical examination abnormalities were reported as AEs. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

    Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)

  2. Number of Participants With Clinically Significant Changes in Vital Signs

    Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: absolute result greater than (\>) 180 millimeter of mercury (mmHg) and \>40 mmHg increase from baseline (BL) and less than (\<) 90 mmHg and \>30 mmHg decrease from BL; diastolic blood pressure (DBP) values: absolute result \>105 mmHg and \>30 mmHg increase from BL and absolute result \< 50 mmHg and \>20 mmHg decrease from BL; any abnormalities in SBP or DBP; heart rate values: absolute result \> 120 beats per minute (bpm) and \>30 bpm increase from BL and absolute result \< 50 bpm and \>20 bpm decrease from BL or any abnormalities in heart rate. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

    Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)

  3. Number of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG)

    Any new post baseline abnormality was defined as any abnormal ECG finding that appeared after baseline assessment which was not seen at the screening or baseline ECG assessment. Where, criteria of abnormality was QTcF interval \> 470 millisecond (msec). Participants were counted once only for a specific abnormality. This outcome measure was planned to be analysed in double blind phase only. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

    Time frame: Baseline, up to the end of DB phase or unscheduled visit (up to 24 months)

  4. Number of Participants With Grade 3/4 Post-Baseline Laboratory Toxicity (Hematology and Chemistry)

    Laboratory parameters included hematological and chemistry parameters. Chemistry parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, creatine kinase, creatinine, glucose, magnesium, phosphate, potassium and sodium. Hematology parameters included haemoglobin, leukocytes, lymphocytes, neutrophils and platelet. Test abnormalities were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 as Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

    Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)

07

Results

Posted Oct 30, 2012
Limitations and caveats
The primary objectives (overall survival) of the study had been met and all participants who had remained on study treatment have discontinued and therefore the study has been considered as completed.

Participant flow

A total of 1199 participants were enrolled and randomized for double-blind (DB) phase. Out of which, 159 participants entered the optional open-label extension (OLE) phase.

DB Phase (up to 24 Months)
Participant flow — DB Phase (up to 24 Months)
MilestoneEnzalutamidePlacebo
Started800399
Completed10950
Not completed691349
Withdrew: Lost to follow-up52
Withdrew: Death561298
Withdrew: Withdrawal by subject167
Withdrew: Study terminated by sponsor10842
Withdrew: Other10
OLE Phase (up to 77 Months)
Participant flow — OLE Phase (up to 77 Months)
MilestoneEnzalutamidePlacebo
Started10950
Completed00
Not completed10950
Withdrew: Death1421
Withdrew: Study terminated by sponsor7826
Withdrew: Other152
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryOverall Survival

Survival was defined as time from randomization to death due to any cause. The duration of overall survival was right-censored for participants who were lost to follow-up since randomization or not known to have died at the data analysis cut-off date (this included participants who were known to have died after the data analysis cut-off date).

Time frame:
During study period (up to 101 months)
Reported as:
Median · Months
Overall Survival
MonthsEnzalutamidePlacebo
Overall Survival18.4 (17.3 to NA)13.6 (11.3 to 15.8)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.63 · 95% CI 0.53 to 0.75Hazard Ratio and 95% confidence interval are from Cox regression model.
SecondaryRadiographic Progression-free Survival

Radiographic progression-free survival was defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Participants were assessed for objective disease progression at regularly scheduled visits. The consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 were taken into consideration for the determination of disease progression. Radiographic disease progression was defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue disease, or the appearance of two or more new bone lesions on bone scan. Progression at the first scheduled reassessment at Week 13 required a confirmatory scan 6 or more weeks later. Participants who did not reach the endpoint were right censored at their last assessment.

Time frame:
During DB phase (up to 24 months)
Reported as:
Median · Months
Radiographic Progression-free Survival
MonthsEnzalutamidePlacebo
Radiographic Progression-free Survival8.3 (8.2 to 9.4)2.9 (2.8 to 3.4)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.40 · 95% CI 0.35 to 0.47Hazard Ratio and 95% confidence interval are from Cox regression model.
SecondaryTime to First Skeletal-related Event

The time to first skeletal-related event was defined as time from randomization to the occurrence of the first skeletal-related event. Participants were assessed for skeletal-related events at regularly scheduled visits. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. Participants who did not reach the endpoint were right censored at their last assessment.

Time frame:
During DB Phase (up to 24 months)
Reported as:
Median · Months
Time to First Skeletal-related Event
MonthsEnzalutamidePlacebo
Time to First Skeletal-related Event16.7 (14.6 to 19.1)13.3 (9.9 to NA)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.69 · 95% CI 0.566 to 0.835Hazard Ratio and 95% confidence interval are from Cox regression model.
SecondaryPercentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)

The FACT-P was a 39-item participant questionnaire which assessed physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The sum of scores on all 5 domains constitutes the global FACT-P. The global/total FACT-P score ranged from 0 (worst) to 156 (best), higher scores indicate better health status. Responders were those participants who had a 10-point improvement in their total FACT-P score, as compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.

Time frame:
Baseline up to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Percentage of participantsEnzalutamidePlacebo
Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)43.2 (39.3 to 47.1)18.3 (13.8 to 23.6)
Statistical analysis
  • Enzalutamide vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage of participants: 24.9 · 95% CI 18.8 to 30.9Confidence Interval based on standard normal approximation.
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was defined as time from randomization to PSA progression. Participants who did not reach the endpoint were right censored at their last assessment or for participants with no post-baseline PSA assessment, date of randomization. For participants with PSA declines at Week 13, the PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 nanogram per milliliter (ng/mL) above the nadir was documented, which was confirmed by a second consecutive value obtained 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment). For participants with no PSA declines at Week 13, PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment).

Time frame:
Baseline and at every study visit from Week 13 while on study drug (up to 24 months)
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsEnzalutamidePlacebo
Time to Prostate-specific Antigen (PSA) Progression8.3 (5.8 to 8.3)3.0 (2.9 to 3.7)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (Stratified by baseline ECOG performance status and mean Brief Pain Inventory - Short Form score (Question #3).) · Hazard ratio (hr): 0.248 · 95% CI 0.204 to 0.303Hazard Ratio and 95% confidence interval are from Cox regression model.
SecondaryPercentage of Participants With Pain Palliation

The proportion of participants with pain palliation was assessed for participants with a stable and sufficient pain burden at study entry. Pain burden was measured by question #3 of the Brief Pain Inventory (Short Form). This scale measures pain on a 0 to 10 scale with 0 indicating no pain and 10 indicating pain as bad as you can imagine. Pain palliation at Week 13 was determined for the proportion of men with baseline bone metastasis(es) who had baseline pain attributable to the metastasis(es). Palliation was defined as \>=30% reduction in average pain score at Week 13 compared to baseline without a \>=30% increase in analgesic use.

Time frame:
Baseline up to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Palliation
Percentage of participantsEnzalutamidePlacebo
Percentage of Participants With Pain Palliation44.9 (30.7 to 59.8)6.7 (0.2 to 31.9)
Statistical analysis
  • Enzalutamide vs Placebo · Cochran-Mantel-Haenszel · p = 0.0079 · Difference in rate of pain palliation: 38.2 · 95% CI 19.4 to 57.0Confidence Interval based on standard normal approximation.
SecondaryPercentage of Participants With Prostate Specific Antigen (PSA) Response

Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \> 50% and \> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.

Time frame:
During DB phase (up to 24 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Prostate Specific Antigen (PSA) Response
Percentage of participantsEnzalutamidePlacebo
Decline >=50% from baseline542
Decline >=90% from baseline251
SecondaryPercentage of Participants With Soft-tissue Objective Response

The best overall soft tissue response as assessed using RECIST v1.1 during the study was summarized using the investigators' response assessments and also the derived response assessments by treatment group. Only participants with measurable soft tissue disease at screening were included in this analysis. Participants with measurable disease at screening are participants who had at least 1 target lesion identified per RECIST v1.1 at screening. Percentage of participants summarizes the number of participants with complete or partial objective response (%). Soft Tissue assessment based on Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.

Time frame:
During DB phase (up to 24 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Soft-tissue Objective Response
Percentage of participantsEnzalutamidePlacebo
Percentage of Participants With Soft-tissue Objective Response294
SecondaryEuropean Quality of Life Five-Domain (EQ-5D) Scale

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Five parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were assessed on 3-point categorical scale (1= no problems, 2= some/moderate problems and 3= severe problem). Score were transformed and resulted in a total EQ-5D score range of 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health and quality of life.

Time frame:
Week 13
Reported as:
Mean · units on a scale
European Quality of Life Five-Domain (EQ-5D) Scale
units on a scaleEnzalutamidePlacebo
European Quality of Life Five-Domain (EQ-5D) Scale67.2 ± 19.2960.0 ± 19.26
SecondaryPercentage of Participants With Circulating Tumor Cell (CTC) Conversion

CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.

Time frame:
Baseline up to 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With Circulating Tumor Cell (CTC) Conversion
percentage of participantsEnzalutamidePlacebo
Percentage of Participants With Circulating Tumor Cell (CTC) Conversion48 (39.09 to 57.07)9.7 (3.63 to 19.88)
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes or deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events which occurred between first dose of study drug and up to the safety follow-up visit or the initiation of another anti-neoplastic therapy, whichever occurred first (up to 101 months). AEs included both serious and non-serious AEs. Clinically significant physical examination abnormalities were reported as AEs. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

Time frame:
Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsEnzalutamidePlacebo: DB PhasePlacebo (DB) /Enzalutamide 160 mg (OLE) Phase
AEs78939048
SAEs31915525
Other pre-specifiedNumber of Participants With Clinically Significant Changes in Vital Signs

Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: absolute result greater than (\>) 180 millimeter of mercury (mmHg) and \>40 mmHg increase from baseline (BL) and less than (\<) 90 mmHg and \>30 mmHg decrease from BL; diastolic blood pressure (DBP) values: absolute result \>105 mmHg and \>30 mmHg increase from BL and absolute result \< 50 mmHg and \>20 mmHg decrease from BL; any abnormalities in SBP or DBP; heart rate values: absolute result \> 120 beats per minute (bpm) and \>30 bpm increase from BL and absolute result \< 50 bpm and \>20 bpm decrease from BL or any abnormalities in heart rate. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

Time frame:
Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsEnzalutamidePlacebo: DB PhasePlacebo (DB) /Enzalutamide 160 mg (OLE) Phase
SBP: >180 mmHg and >40 mmHg Increase from BL2871
SBP: < 90 mmHg and >30 mmHg Decrease from BL1350
DBP: >105 mmHg and >30 mmHg Increase from BL520
DBP: < 50 mmHg and >20 mmHg Decrease from BL1331
Any abnormalities in SBP or DBP52162
Heart Rate: > 120 bpm and >30 bpm Increase from BL750
Heart Rate: < 50 bpm and >20 bpm Decrease from BL1810
Any abnormalities in Heart Rate2560
Other pre-specifiedNumber of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG)

Any new post baseline abnormality was defined as any abnormal ECG finding that appeared after baseline assessment which was not seen at the screening or baseline ECG assessment. Where, criteria of abnormality was QTcF interval \> 470 millisecond (msec). Participants were counted once only for a specific abnormality. This outcome measure was planned to be analysed in double blind phase only. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

Time frame:
Baseline, up to the end of DB phase or unscheduled visit (up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG)
ParticipantsEnzalutamidePlacebo: DB Phase
Number of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG)2813
Other pre-specifiedNumber of Participants With Grade 3/4 Post-Baseline Laboratory Toxicity (Hematology and Chemistry)

Laboratory parameters included hematological and chemistry parameters. Chemistry parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, creatine kinase, creatinine, glucose, magnesium, phosphate, potassium and sodium. Hematology parameters included haemoglobin, leukocytes, lymphocytes, neutrophils and platelet. Test abnormalities were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 as Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.

Time frame:
Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3/4 Post-Baseline Laboratory Toxicity (Hematology and Chemistry)
ParticipantsEnzalutamidePlacebo: DB PhasePlacebo (DB) /Enzalutamide 160 mg (OLE) Phase
Alanine Aminotransferase:High221
Albumin: Low730
Alkaline Phosphatase: High102743
Aspartate Aminotransferase: High341
Bilirubin: High200
Calcium: Low14151
Calcium: High100
Creatine Kinase: High420
Creatinine: High020
Glucose: High17101
Magnesium: Low010
Magnesium: High110
Phosphate: Low28102
Potassium: Low741
Potassium: High230
Sodium: Low19130
Sodium: High010
Hemoglobin: Low38204
Hemoglobin: High100
Leukocytes: Low811
Lymphocytes: Low80485
Neutrophils: Low1001
Platelet; Low440

Adverse events

Collected over Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide: DB + OLE Phase—319/800 (39.9%)784/800 (98%)
Placebo: DB Phase—155/399 (38.8%)385/399 (96.5%)
Placebo (DB) /Enzalutamide 160 mg (OLE) Phase—25/50 (50%)47/50 (94%)
Most frequent serious events
Showing 10 of 308
Most frequent serious events
EventEnzalutamide: DB + OLE PhasePlacebo: DB PhasePlacebo (DB) /Enzalutamide 160 mg (OLE) Phase
Spinal cord compressionNervous system disorders54/80015/3993/50
General physical health deteriorationGeneral disorders22/8008/3993/50
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)18/8003/3993/50
AnaemiaBlood and lymphatic system disorders22/80012/3992/50
Cardiac failureCardiac disorders3/8002/3992/50
ConvulsionNervous system disorders4/8000/3992/50
Disease progressionGeneral disorders1/8000/3992/50
HaematuriaRenal and urinary disorders18/8005/3991/50
VomitingGastrointestinal disorders3/8008/3991/50
Urinary retentionRenal and urinary disorders7/8008/3990/50
Most frequent other events
Showing 10 of 41
Most frequent other events
EventEnzalutamide: DB + OLE PhasePlacebo: DB PhasePlacebo (DB) /Enzalutamide 160 mg (OLE) Phase
NauseaGastrointestinal disorders276/800166/39916/50
FatigueGeneral disorders280/800115/39914/50
Decreased appetiteMetabolism and nutrition disorders246/800121/3999/50
Back painMusculoskeletal and connective tissue disorders225/80091/3999/50
ConstipationGastrointestinal disorders209/800109/3997/50
ArthralgiaMusculoskeletal and connective tissue disorders182/80071/3992/50
DiarrhoeaGastrointestinal disorders180/80070/3999/50
AnaemiaBlood and lymphatic system disorders123/80070/39911/50
VomitingGastrointestinal disorders141/80084/3998/50
Hot flushVascular disorders165/80041/3991/50

Baseline characteristics

Intent-to-treat population (ITT) included all participants who were randomized into the study.

Age, Categorical
Age, Categorical(Participants)EnzalutamidePlaceboTotal
<=18 years000
Between 18 and 65 years232130362
>=65 years568269837
Age, Continuous
Age, Continuous(years)EnzalutamidePlaceboTotal
Mean68.8 ± 7.9668.6 ± 8.3968.7 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)EnzalutamidePlaceboTotal
Female000
Male8003991199
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EnzalutamidePlaceboTotal
Hispanic or Latino322355
Not Hispanic or Latino7683761144
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EnzalutamidePlaceboTotal
American Indian or Alaska Native112
Asian5813
Native Hawaiian or Other Pacific Islander101
Black or African American272047
White7453661111
More than one race000
Unknown or Not Reported21425
Region of Enrollment
Region of Enrollment(Participants)EnzalutamidePlaceboTotal
United States181107288
Spain231336
Austria151025
Chile6511
United Kingdom8250132
Italy201030
France19380273
Canada8225107
Argentina7310
Belgium271845
Poland7411
Australia603393
South Africa336
Germany622486
Netherlands321446
08

Study locations

249 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Premiere Oncology of Arizona
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Tower Cancer Research Foundation, Tower Hematology Oncology Medical Group
    Beverly Hills, California 90211-1850, United States
  • USC Westside Prostate Cancer Center
    Beverly Hills, California 90211, United States
  • City of Hope
    Duarte, California 91010, United States
  • Cancer Center Oncology Medical Group
    La Mesa, California 91942, United States
  • LAC & USC Medical Center
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095-6984, United States
  • UCLA
    Los Angeles, California 90095, United States
  • c/o Prostate Oncology Specialist, Inc.
    Marina Del Rey, California 90292, United States
  • North County Oncology Medical Clinic, Inc,
    Oceanside, California 92056, United States
  • Medical Oncology Associates - SD
    San Diego, California 92123, United States
  • Sharp Memorial Hospital Investigational Pharmacy
    San Diego, California 92123, United States
  • Sharp Rees-Stealy
    San Diego, California 92123, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94115, United States
  • City of Hope Medical Group
    South Pasadena, California 91030, United States
  • Stanford Hospital and Clinics Research Pharmacy
    Stanford, California 94305, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Research Pharmacist
    Aurora, Colorado 80045, United States
  • University of Colorado Denver, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • C/O: Thomas Ferencz R.Ph., BCOP
    New Haven, Connecticut 06510, United States
  • Yale University School of Med
    New Haven, Connecticut 06520, United States
  • George Washington University-Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Palm Beach Cancer Institute
    Atlantis, Florida 33462, United States
  • Palm Beach Cancer Institute
    Palm Beach Gardens, Florida 33410, United States
  • Palm Beach Cancer Institute
    Wellington, Florida 33414, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Peachtree Hematology-Oncology Consultants, P.C.
    Atlanta, Georgia 30318, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital (MGH)
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital (BWH)
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Weisberg Cancer Treatment Center
    Farmington Hills, Michigan 48334, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Siteman Cancer Center-West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110-1094, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center
    Saint Peters, Missouri 63376, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Nevada Cancer Institute, an affiliate of the UC San Diego Health System
    Las Vegas, Nevada 89135, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New Mexico Oncology Hematology Consultants, Ltd.
    Albuquerque, New Mexico 87109, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10021, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Pharmaceutical Research Services
    Durham, North Carolina 27710, United States
  • Portland VA Medical Center
    Portland, Oregon 97239, United States
  • UPMC Cancer Centers
    McKeesport, Pennsylvania 15132, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15232, United States
  • UPMC Cancer Centers
    Pittsburgh, Pennsylvania 15237, United States
  • VA Pittsburgh Healthcare System
    Pittsburgh, Pennsylvania 15240, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Grand Strand Urology
    Myrtle Beach, South Carolina 29572, United States
  • Tennessee Oncology, PLLC
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology, PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • Tennessee Oncology, PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37087, United States
  • Tennessee Oncology, PLLC
    Murfreesboro, Tennessee 37129, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37205, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5536, United States
  • Tennessee Oncology, PLLC
    Smyrna, Tennessee 37167, United States
  • Parkland Health and Hospital System
    Dallas, Texas 75235, United States
  • Texas Oncology, Sammons Cancer Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Virginia Oncology Associates
    Chesapeake, Virginia 23320, United States
  • Virginia Oncology Associates
    Hampton, Virginia 23666, United States
  • Virginia Cancer Institute
    Mechanicsville, Virginia 23116-1844, United States
  • Virginia Cancer Institute
    Midlothian, Virginia 23114, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23235-4730, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • Virginia Oncology Associates
    Williamsburg, Virginia 23188, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Instituto Medico de Asistencia e Investigaciones S.A (IMAI Research)
    Buenos Aires, AR C1425AWC, Argentina
  • Instituto Oulton
    Cordoba, Provincia DE Cordoba X5000JJS, Argentina

Showing the first 100 of 249 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22. PubMed 35731340 ↗
  • Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26. PubMed 35643841 ↗
  • Zhao JL, Fizazi K, Saad F, Chi KN, Taplin ME, Sternberg CN, Armstrong AJ, de Bono JS, Duggan WT, Scher HI. The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clin Cancer Res. 2022 Mar 1;28(5):860-869. doi: 10.1158/1078-0432.CCR-21-1090. PubMed 34965947 ↗
  • Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):288-295. doi: 10.1038/s41391-021-00447-9. Epub 2021 Sep 13. PubMed 34518652 ↗
  • Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. JAMA Oncol. 2020 Feb 1;6(2):217-225. doi: 10.1001/jamaoncol.2019.4636. PubMed 31830211 ↗
  • Poon DMC, Wong KCW, Chan TW, Law K, Chan K, Lee EKC, Lee C, Chan M; Hong Kong Society of Uro-Oncology (HKSUO). Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong. Clin Genitourin Cancer. 2018 Oct;16(5):402-412.e1. doi: 10.1016/j.clgc.2018.07.008. Epub 2018 Jul 21. Erratum In: Clin Genitourin Cancer. 2019 Jun;17(3):240. doi: 10.1016/j.clgc.2018.12.008. PubMed 30126765 ↗
  • Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. PubMed 29272162 ↗
  • Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015 Nov;51(17):2570-7. doi: 10.1016/j.ejca.2015.07.042. Epub 2015 Aug 13. PubMed 26278649 ↗
  • Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J. Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5. PubMed 25917876 ↗
  • Cella D, Ivanescu C, Holmstrom S, Bui CN, Spalding J, Fizazi K. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol. 2015 Jan;26(1):179-185. doi: 10.1093/annonc/mdu510. Epub 2014 Oct 30. PubMed 25361992 ↗
  • Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol. 2015 Feb;67(2):223-30. doi: 10.1016/j.eururo.2014.08.025. Epub 2014 Aug 27. PubMed 25171902 ↗
  • Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015 Jan;115(1):41-9. doi: 10.1111/bju.12898. Epub 2014 Oct 23. PubMed 25123978 ↗
  • Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014 Sep;15(10):1147-56. doi: 10.1016/S1470-2045(14)70303-1. Epub 2014 Aug 4. Erratum In: Lancet Oncol. 2014 Oct;15(11):e475. PubMed 25104109 ↗
  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. PubMed 22894553 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Sep 2011, 23 months.

Results were first posted in Oct 2012, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 23 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2009
First posted
Sep 10, 2009
StartActual
Sep 30, 2009
Primary completionActual
Sep 15, 2011
CompletionActual
Nov 2, 2017
Results first posted
Oct 30, 2012
Last update
Dec 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00974311
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Sep 10, 2009
Start date
Sep 30, 2009
Primary completion
Sep 15, 2011
Completion
Nov 2, 2017
Results posted
Oct 30, 2012
Last update
Dec 11, 2018

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion